Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

BACKGROUND: The primary objective of this study was to investigate if hepatic impairment alters the safety, pharmacokinetics, and pharmacodynamics of HSK3486. RESEARCH DESIGN AND METHODS: This was a clinical trial of HSK3486 in subjects with normal hepatic function (n = 8), and mild (Child-Pugh A; n...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yue, Li, Xiaojiao, Liu, Jingrui, Chen, Hong, Zheng, Wenbo, Zhang, Hong, Wu, Min, Li, Cuiyun, Zhu, Xiaoxue, Lou, Jinfeng, Yan, Pangke, Wu, Nan, Liu, Xiao, Ma, Shiping, Wang, Xu, Ding, Yanhua, Xuan, Chengluan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Gastroenterology & Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559057/
https://www.ncbi.nlm.nih.gov/pubmed/36217101
http://dx.doi.org/10.1080/07853890.2022.2129433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559057/
https://www.ncbi.nlm.nih.gov/pubmed/36217101
http://dx.doi.org/10.1080/07853890.2022.2129433

Ejemplares similares